Accelerated Medical Diagnostics (United States)

Traditional financial institutions (TFIs), particularly community banks and small asset management firms (SAMFs) with assets under $50 billion, face a trifecta of bottlenecks when accessing Web3: prohibitive technical barriers, fragmented regulatory compliance risks, and cognitive dissonance between crypto asset valuation and traditional financial logic. In the U.S. market, constrained by multi-agency oversight (SEC, OFAC, FinCEN), the adoption rate of Web3 access among these small TFIs remains merely 5.2% (SIFMA, 2025), far below the 37.8% penetration among large institutions with assets exceeding$500 billion. Leveraging my dual expertise in quantitative finance (CFA Level III) and Web3 multi-chain development (Uniswap V3/V4 protocol experience, daos.world multi-chain DAO incubation), this study constructs a three-dimensional synergistic theoretical framework integrating regulatory adaptation, technical simplification, and valuation migration. A low-barrier access pathway is proposed, centered on the “TradFi-Web3 Connector” system—featuring compliant wallet custody based on EIP-4337 account abstraction and a traditional finance-derived Web3 asset valuation model. Empirical validation across 8 U.S. small TFIs (4 community banks, 4 SAMFs) over an 8-month period (March–October 2025) demonstrates that this pathway reduces the average onboarding cycle from 2.8 months to 9.7 days (82.5% improvement), cuts compliance costs by 61.3% (from $95,400 to$37,300 per annum), achieves a 92.4% investment decision accuracy rate, and maintains a 100% pass rate in SEC compliance reviews with zero regulatory incidents. This research fills a critical gap in low-barrier Web3 access for resource-constrained TFIs, provides a replicable paradigm for the digital transformation of U.S. traditional finance, and empirically validates the synergy between regulatory compliance and technical innovation in cross-ecosystem integration.

“AI-driven models can detect subtle variations in how women respond to certain medications, or how autoimmune diseases present differently across genders.”A two-week travel diary uncovering the market potential in addressing the gender gap, by Helena Strigård, Founder, Ventures Accelerated.

Hardware complexity continues to strain verification resources, motivating the adoption of machine learning (ML) methods to improve debug efficiency. However, ML-assisted debugging critically depends on diverse and scalable bug datasets, which existing manual or automated bug insertion methods fail to reliably produce. We introduce BugGen, a first of its kind, fully autonomous, multi-agent pipeline leveraging Large Language Models (LLMs) to systematically generate, insert, and validate realistic functional bugs in RTL. BugGen partitions modules, selects mutation targets via a closed-loop agentic architecture, and employs iterative refinement and rollback mechanisms to ensure syntactic correctness and functional detectability. Evaluated across five OpenTitan IP blocks, BugGen produced 500 unique bugs with 94% functional accuracy and achieved a throughput of 17.7 validated bugs per hour—over five times faster than typical manual expert insertion. Additionally, BugGen identified 104 previously undetected bugs in OpenTitan regressions, highlighting its utility in exposing verification coverage gaps. Compared against Certitude, BugGen demonstrated over twice the syntactic accuracy, deeper exposure of testbench blind spots, and more functionally meaningful and complex bug scenarios. Furthermore, when these BugGen-Generated datasets were employed to train ML-based failure triage models, we achieved high classification accuracy (88.1%–93.2%) across different IP blocks, confirming the practical utility and realism of generated bugs. BugGen thus provides a scalable solution for generating high-quality bug datasets, significantly enhancing verification efficiency and ML-assisted debugging.

IntroductionEnrolling children with cancer in early phase trials is crucial to access innovative treatments, contributing to advancing pediatric oncology research and providing tailored therapeutic options. Our objective is to analyze the impact of these trials on patient outcomes and safety, and to examine the evolution and feasibility of trials in pediatric cancer over the past decade.MethodsAll patients recruited in pediatric anticancer phase I/II clinical trials from January 2014 to December 2022 were included. Clinical records and trial protocols were analyzed.ResultsA total of 215 patients (median age 11.2 years, range 1–29.5) were included in 52 trials (258 inclusions). Patients with extracranial solid tumors (67%), central nervous system (CNS) tumors (24%), and leukemia (9%) were included. The most common investigational drugs were small molecules (28.3%) and antibodies (20.5%). Serious adverse events were experienced by 41% of patients, 4.4% discontinued treatment because of toxicity and two had toxic deaths. Median event-free survival was 3.7 months (95%CI: 2.8–4.5), longer in phase II trials than in phase I (2 vs. 6.3 months; p ≤ 0.001). Median overall survival was 12 months (95%CI: 9–15), higher in target-specific vs. non-target-specific trials (14 vs. 6 months; p ≤ 0.001).DiscussionA significant and increasing number of patients have been included in early clinical trials, suggesting that both oncologists and families consider it valuable to be referred to specialized Units to access new therapies. Moreover, our data suggests that participation in early clinical trials, although not without potential toxicities, might have a positive impact on individual outcomes.

Accelerated 3-year programs (A3YPs) at medical schools were developed to address student debt and mitigate workforce shortage issues. This study investigated whether medical school length (3 vs 4 years) was associated with early residency performance. The primary research question was as follows: Are the Accreditation Council for Graduate Medical Education Milestones (MS) attained by A3YP graduates comparable to graduates of traditional 4-year programs (T4YPs) at 6 and 12 months into internship? The MS data from students entering U.S. medical schools in 2021 and 2022 from the 6 largest specialties were used: emergency medicine, family medicine, internal medicine, general surgery, psychiatry, and pediatrics. Three-year and 4-year graduates were matched for analysis (2,899 matched learners: 182 in A3YPs and 2,717 in T4YPs). The study used a noninferiority study design to examine data trends between the study cohort (A3YP) and control cohort (T4YP). To account for medical school and residency program effects, the authors used cross-classified random-effects regression to account for clustering and estimate group differences. The mean Harmonized MS ratings for the midyear and end-year reporting periods showed no significant differences between the A3YP and T4YP groups (mean [SE] cross-classified coefficient = 0.01 [0.02], P = .77). Mean MS ratings across internal medicine MS for the midyear and end-year reporting periods showed no significant differences between the A3YP and T4YP groups (mean [SE] cross-classified coefficient = -0.03 [0.03], P = .31). Similarly, for family medicine, there were no statistically significant differences between the A3YP and T4YP groups (mean [SE] cross-classified coefficient = 0.01 [0.02], P = .96). For the specialties studied, there were no significant differences in MS performance between 3-year and 4-year graduates at 6 and 12 months into internship. These results support comparable efficacy of A3YPs in preparing medical students for residency.

It is now assumed that all hard-to-heal wounds contain biofilm. Debridement plays a key role in wound-bed preparation, as it can remove biofilm along with the devitalised tissue, potentially leaving a clean wound bed that is more likely to progress towards healing. The gold standard methods of debridement (surgical and sharp) are the least used, as they require specialist training and are often not readily available at the point of need. Most other methods can be used by generalists but are slower. They all need regular applications. The topical desiccating agent DEBRICHEM is an innovative alternative, as it is fast, effective and can be used in all clinical settings, as well as typically requiring only a single use. This article describes best practice for achieving optimal outcomes with its use.

Better therapies for childhood cancer remain an unmet need to improve the dismal prognosis of certain malignancies and to reduce the burden of toxicity. Rescuing discontinued or shelved drugs for children, adolescents, and young adults is a strategy to identify new uses for approved or investigational medicines outside the scope of their original medical indication. Our proposed multistakeholder consensus focuses on the development of innovative, patent-protected targeted agents, sourced from previously shelved or discontinued programs that have the potential to provide significant benefit to underserved patient populations, with unmet medical needs. There are several challenges to continuing/rescuing drugs for pediatric oncology development, which include the lack of information for decision making, corporate strategy considerations underlying the decision to invest in pediatric development, and the contracting and technology transfer complexities required to enable divestment and subsequent development. The multistakeholder approach for drug development has the advantage of conveying a consensus among academia, patient advocates, and importantly industry itself. We propose three areas of action to facilitate rescuing potentially beneficial drugs for children and adolescents with cancer: (i) initiatives to provide information to companies considering developing these drugs and a standards framework; (ii) incentives both in Europe and in the United States to encourage companies to develop pediatric-only drugs, with the reform of the EU Pharmaceutical Legislation posing an important opportunity; and (iii) communication of the issues to all stakeholders. Ultimately, this will benefit children and adolescents with cancer.

The American College of Surgeons and state regulations mandate that trauma facilities offer trauma-specific continuing education throughout the region they serve. These requirements come with unique challenges when serving a rural and sparsely populated state. A novel approach to providing education was necessitated by the coronavirus disease 2019 pandemic, travel distance, and limited local specialists. The purpose of this article is to describe the development of a virtual educational program used to improve access to quality trauma education and decrease barriers to obtaining continuing education hours inherent in the region. This article describes the development and implementation of the Virtual Trauma Education program, which provided one free continuing education hour per month from October 2020 to October 2021. The program reached more than 2,000 viewers and established a method to provide continuous monthly educational offerings throughout the region. After the Virtual Trauma Education program implementation, monthly educational attendance increased from an average of 55 to 190. Viewership data indicate that trauma education across our region is far more robust, available, and accessible using a virtual platform. With more than 2,000 views from October 2020 to October 2021, Virtual Trauma Education offerings have spread far beyond regional borders, reaching 25 states and 169 communities. Virtual Trauma Education delivers easily accessible trauma education and is a program that has proven its sustainability.

On comparing the Humphrey Field Analyzer (HFA) 24-2C Faster, which tests 10 additional points in the central field, with the 24-2 Swedish Interactive Thresholding Algorithm (SITA) Standard for detecting central field defects, we found that the HFA 24-2C Faster may be used for the initial field evaluation in glaucoma with the advantage of a shorter testing time. This study aimed to compare the HFA 24-2C Faster with the 24-2 SITA Standard and 10-2 among patients with glaucoma for the number of defective central points, global indices, and testing time. Sixty eyes of 60 patients with glaucoma and glaucomatous visual field defects on the 24-2 SITA Standard algorithm underwent the 24-2C Faster and 10-2 field tests. The number of central points detected, global indices, and reliability indices were compared between the 24-2C Faster and the 24-2 SITA Standard and 10-2 field tests. The 24-2C Faster, on average, detected 5.5 defective points more on the total deviation plot and 2 defective points more on the pattern deviation plot than the 24-2 SITA Standard in central 10°. The 10-2 algorithm detected 2.5 times more points on the total deviation plot than the 24-2C Faster. There was excellent consistency by an intraclass correlation coefficient of 0.95 for the mean deviation and 0.93 for the pattern standard deviation between the 24-2C Faster and the 24-2 SITA Standard. There was good consistency by an intraclass correlation coefficient of 0.80 for both mean deviation and pattern standard deviation between the 24-2C Faster and the 10-2. The testing time was significantly lower with the 24-2C Faster compared with the 24-2 SITA Standard and 10-2 test. Our study demonstrates that the HFA 24-2C Faster may be used for the initial evaluation of the visual field in glaucoma with the added advantage of a shorter testing time compared with the 24-2 SITA Standard program.

Journal of Wound CareVol. 32, No. Sup3b Case StudyCase studiesPriti Bhatt, Emma Bennett, Sarah Molden, Katie Leek, Annabelle Mooney, Hayley Turner-DobbinPriti BhattCommunity Tissue Viability Nurse Specialist Lead, Guy's & St Thomas' NHS Foundation TrustSearch for more papers by this author, Emma BennettSenior Sister for Tissue Viability, University Hospital of North MidlandsSearch for more papers by this author, Sarah MoldenVascular Nurse Specialist, University Hospital of North MidlandsSearch for more papers by this author, Katie LeekClinical Lead for Tissue Viability and Continence, University Hospital of North MidlandsSearch for more papers by this author, Annabelle MooneyNurse Specialist, Bradford District Care NHS Foundation TrustSearch for more papers by this author, Hayley Turner-DobbinClinical Delivery Lead, AccelerateSearch for more papers by this authorPriti Bhatt; Emma Bennett; Sarah Molden; Katie Leek; Annabelle Mooney; Hayley Turner-DobbinPublished Online:27 Mar 2023https://doi.org/10.12968/jowc.2023.32.Sup3b.S13AboutSectionsView articleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareShare onFacebookTwitterLinked InEmail View article